A new three-drug combination is being tested on extensively drug-resistant TB cases in Tajikistan.
Dolutegravir, an anti-HIV drug that may be key to reducing the global incidence of TB, awaits large-scale clinical trials.
Our webfeeds enable you to embed the latest SciDev.Net stories into your website. Simply insert the following code into your web template to activate our latest news and analysis into your site.
> How to set up and customise your webfeed